Diagnostic Performance of T2Candida Among ICU Patients With Risk Factors for Invasive Candidiasis

Arendrup, Maiken Cavling; Andersen, Jakob S; Holten, Mads Kristian; Krarup, Kenneth B; Reiter, Nanna; Schierbeck, Jens; Helleberg, Marie

Published in:
Open Forum Infectious Diseases

DOI:
10.1093/ofid/ofz136

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Arendrup, M. C., Andersen, J. S., Holten, M. K., Krarup, K. B., Reiter, N., Schierbeck, J., & Helleberg, M. (2019). Diagnostic Performance of T2Candida Among ICU Patients With Risk Factors for Invasive Candidiasis. Open Forum Infectious Diseases, 6(5). https://doi.org/10.1093/ofid/ofz136
Diagnostic Performance of T2Candida Among ICU Patients With Risk Factors for Invasive Candidiasis

Maiken Cavling Arendrup,1,2 Jakob S. Andersen,4a Mads Kristian Holten,5a Kenneth B. Krarup,4a Nanna Reiter,4a Jens Schierbeck,5 and Marie Helleberg6

1Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark; 2Department of Clinical Microbiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 3Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; 4Department of Intensive Care Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 5Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Background. Invasive candidiasis (IC) comprises candidemia and deep-seated candidiasis. Blood culture (BC) is the gold standard test, but sensitivity is low. T2Candida is a new diagnostic test. We investigated the performance of T2Candida, BC, and Candida mannann antigen (MAg) for detection of IC in a high-risk intensive care unit (ICU) population.

Methods. One-hundred twenty-six ICU patients at high risk of IC with sepsis despite 3 days of broad-spectrum antibiotics were included. Paired BC, T2Candida, and MAg were obtained twice weekly (334 sets). Patients were classified into proven, likely, possible, or unlikely IC based on patient record review.

Results. At enrollment, 92 (77%) patients were receiving antifungal therapy (mainly fluconazole 66%). Fifteen (11.9%) patients were positive by BC (n = 4), T2Candida (n = 11), or MAg (n = 10). The T2Candida species distribution at inclusion (Candida albicans/Candida tropicalis: 8/11 [72.3%] and Candida glabrata/Candida krusei: 3/11 [27.3%]) was supported by the identification of BC or colonizing isolates in 10/11 cases. Patients were classified with proven (11), likely (6), possible (11), and unlikely (98) IC. Defining IC as proven/proven&likely/proven&likely&possible, respectively, the sensitivity was as follows: T2Candida (55%/59%/39%), BC (45%/29%/8%), and MAg (36%/41%/32%). The negative predictive value was similar across the tests for proven vs others and proven/likely vs others (94%–96% and 90%–95%, respectively). For test combinations including T2Candida, the sensitivity increased to 64%–65%, without hampering the positive predictive value.

Conclusions. In conclusion, although the diagnostic performance was modest for all the tests, the combination of T2Candida and BC seemed to have the best diagnostic performance, and thus implementation of T2Candida may improve the diagnosis of IC.

Keywords. blood culture; Candida; candida mannann antigen; diagnostic performance; intensive care unit.
patients with severe abdominal conditions [20]. The variation in reported performance for this test remains unexplained, but in a population mainly at risk of candidiasis, a Candida-specific rather than panfungal test may be preferable with respect to risk of false-positive results and interpretation.

The T2Candida molecular test has recently been Conformité Européenne (CE) marked and Food and Drug Administration (FDA) cleared. The test detects (1) C. albicans and C. tropicalis, reported together as C. albicans/C. tropicalis; (2) C. glabrata, C. krusei, S. cerevisiae, and C. bracarensis, reported together as C. glabrata/C. krusei; and (3) C. parapsilosis, C. orthopsilosis, and C. metapsilosis, reported as C. parapsilosis. Together, these species formed the majority (93.5%) of the Candida bloodstream infections in Denmark in 2012–2015 [11]. The combined sensitivity and specificity of the test for detecting candidemia were 91.1% and 99.4%, respectively, in the study that led to the FDA clearance [32]. Subsequent studies have confirmed a high sensitivity using seeded blood samples [33] and when comparing the results for follow-up BGs and T2Candida tests obtained from pediatric and adult patients with documented candidemia [14, 34]. Moreover, among patients already receiving antifungal therapy, the T2Candida assay yielded positive results in a number of cases with negative BC [14]. Of note, studies performed so far included candidemic patients with or without enrichment of the study material with spiked blood samples. Hence the performance in cases with IC without concomitant candidemia is largely unknown.

In this study, we compared the diagnostic performance of BC, T2Candida, and Candida MAg and MAb in patients at risk of IC in the 2 major university ICUs in a country with a high incidence of IC [11, 35]. To our knowledge, it is the largest and only non-single-center prospective study performed in a high-risk ICU setting for comparative diagnosis of IC.

**METHODS**

**Patients and Data Collection**

In total, 126 ICU patients were included during the study period of October 1, 2014, to June 21, 2016. The characteristics at 2 major university ICU units are summarized in Supplementary Table 1.

**Inclusion Criterion**

The inclusion criterion was 1 of the following: (1) initiation of prophylactic, empiric, or preemptive antifungal treatment; (2) colonization index ≥0.5; or 3) temperature >38°C or <36°C despite 3 days of broad-spectrum antibiotic treatment and at least 2 of the following risk factors: abdominal surgery, secondary peritonitis, pancreatitis, central vein catheter (CVC) in place, total parenteral nutrition (TPN), dialysis, steroid treatment, immunosuppressive treatment, or liver transplantation. Patients who fulfilled the inclusion criterion but had candidemia before inclusion were not excluded. Presence or absence of each inclusion criterion was registered, along with each blood sampling. Upon completion of the study, patient records and clinical microbiology test databases were reviewed for each patient. The following data were extracted: underlying diseases, body temperature >38°C or <36°C, signs of sepsis (systolic blood pressure <90 mmHg: mean arterial pressure <65 mmHg; need of vasopressor infusion [epi-/norepinephrine] or blood pressure drop 40 mmHg from baseline), white blood cell count >12 000 cells/µL, confirmation of ≥3 days of broad-spectrum antibiotics. The microbiological tests were reviewed and categorized into whether Candida were isolated from at least 2 nonsterile sites (±3 days) and whether there was an alternative microbiological diagnosis.

From each patient, a 5.5-mL EDTA tube and a BC set were obtained simultaneously at the time of enrollment. The EDTA tube was used for T2Candida (T2 Biosystems, Lexington, MA) and for Platelia Candida MAg and Ab (Bio-Rad, Marnes-la-Coquette, France). Bact/ALERT (bioMérieux, Marcy l’Etoile, France) BC was used in Odense and BACTEC (Becton Dickinson, Franklin Lakes, NJ) at Rigshospitalet. Sampling was repeated twice weekly in Odense for as long as the patient fulfilled the enrollment criteria. At Rigshospitalet, a single follow-up sample set was obtained after 3 days. At both hospitals, routine urine and tracheal secretions were cultured at regular intervals. Additional microbiological tests were performed as indicated by the treating physician.

Cases were classified based on vital signs and results of microbiological examinations within 3 days of enrollment (see below).

**Proven IC**: either (1) growth of Candida in a BC or (2) fulfilling all the following: (i) growth of Candida in a tissue biopsy or sample from a drain placed within 24 hours, (ii) sampling from a normally sterile site using sterile procedures, and (iii) clinical or radiological signs of infection at that site (EORTC/MSG criteria [9]).

**Likely IC**: either (1) Candida isolated from at least 2 nonsterile sites (±3 days) and no alternative microbiological diagnosis (±3 days) and fulfilling ≥1 SIRS criterion despite 3 days of broad-spectrum antibacterial treatment or (2) Candida MAg >250 mg/L and colonized with Candida at 2 sites (±3 days) (adopted from [25, 36]).

**Possible IC**: either (1) Candida MAg >125 mg/L and colonized at 2 sites (±3 days) or (2) Candida MAg >250 mg/L or (3) Candida isolated from at least 2 nonsterile sites (±3 days) and fulfilling SIRS criteria despite ≥3 days of broad-spectrum antibiotics.

**No IC**: remaining cases.

Subsequently, we studied the medical files of all cases who were initially classified as either proven, likely, or possible IC or who
had at least 1 positive marker for IC (T2 or mannan Ag) and revised the classification according to results of microbiological analyses within 21 days of enrollment and detailed information on clinical course, as presented in Supplementary Table 2.

Statistical Analysis
The sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values of the tests were assessed based on the sample drawn at inclusion and the subsequent sample drawn at day 2 or 3. If analyses of the 2 samples were discordant (ie, 1 positive and 1 negative), the test was considered positive. The Fisher exact test was used to compare the proportions of patients receiving antifungal therapy for BC-positive vs -negative patients.

RESULTS
In total, 334 sample sets from 126 ICU patients at risk for IC were included during the 21-month study period. The median age (range) was 65.5 (16–89) years, and 72 (57%) were men. The majority of patients met more than 1 inclusion criterion (82%) and received antifungal therapy at the time of inclusion (77%) (Table 1). Abdominal surgery was the most common risk factor (44%), followed by secondary peritonitis or immunosuppression.

Microbiology
At the time of enrollment, 15 (11.9%) patients were positive by BC, T2Candida, and/or MAg testing (Figure 1, Table 2). Overall, 7/11 T2Candida-positive samples and 7/10 MAg-positive samples were from patients without a concomitant positive BC at the time of inclusion. Significantly fewer patients with positive compared with negative BCs received antifungal therapy at the time of inclusion (2/5 [40%] vs 90/115 [78%], P = .008). For the T2Candida test and the MAg test, there were no statistically significant associations between test results and antifungal therapy at inclusion (7/11 [64%] vs 80/103 [78%], P = .287, and 9/10 [90%] vs 78/103 [76%], P = .449, respectively).

T2Candida Test Results
The species distribution among patients with initial samples positive in T2Candida was C. albicans/C. tropicalis in 8/11 (72.3%) patients and C. glabrata/C. krusei in 3/11 (27.3%). The T2Candida test was positive for 4/5 patients with positive index BCs and for 2 additional patients with positive BCs 2 and 4 days before inclusion, whereas 5 patients had negative BCs (Table 3). The species group reported by the T2Candida test was confirmed by the identification of BC or colonizing isolates in 10/11 cases (Candida was not identified to the species level in 1 patient), although T2Candida failed to detect the second species at day 0 in a patient with polyfungal infection (Table 3). T2Candida was negative in the patient with C. kefyr candidemia, a species that is not included in the panel, and was invalid in 9/126 (7.1%) patients at enrollment.

Table 1. Baseline Characteristics of the Study Population (126 Patients)a

| Risk factors, No. (%) | Male, No. (%) | Age, median (IQR), y | Inclusion criterion, % |
|----------------------|---------------|----------------------|------------------------|
| Male, No. (%) | 72 (57) | 65.5 (53–75) |
| Central venous catheter | 110/124 (90) | 24/121 (20) |
| Parenteral nutrition | 26/122 (21) |
| Dialysis | 32/121 (26) |
| Steroids | 20/120 (17) |
| Abdominal surgery | 6/120 (5) |
| Secondary peritonitis | 19/121 (16) |
| Pancreatitis | 1/121 (0.8) |
| Dialysis | 27/119 (23) |
| Other azole | 76/119 (63) |
| Echinocandinb | 3/119 (3) |
| Echinocandinb | 14/119 (12) |

Abbreviation: IQR, interquartile range.

aData missing for some patients as indicated by varying denominators.

In 4 BC-negative patients, a single follow-up sample was positive by T2Candida, 3 of these with C. parapsilosis in the absence of concomitant C. parapsilosis colonization or other indication of IC (Table 3). These 3 cases were likely false positives. The fourth patient became positive with C. glabrata/C. krusei, MAg, and MAb at day 4. Including these, the overall species distribution as determined by T2Candida was C. albicans/C. tropicalis 8/15 (53%), C. glabrata/C. krusei 4/15 (27%), and C. parapsilosis 3/15 (20%).

Figure 1. Positive diagnostic samples at the time of inclusion in the study. aBlood culture with Candida kefyr, which is not included in the panel of the T2Candida test. Abbreviations: BC, blood culture; MAg, mannan antigen; Pos., positive; T2, T2Candida.
### Candida Mannan Ag and Ab

The MAg test was positive in 3/5 patients with positive BC at enrollment, including the patient with *C. kefyr* candidemia (Table 3). Seven additional patients were MAg positive at enrollment, 4 of whom were T2Candida positive and 1 of whom had been BC positive 5 and 7 days earlier. During the follow-up period, 4 additional BC-negative patients changed to MAg positive (2 of whom also developed MAb), whereas 5 patients became MAb positive during follow-up (1 of whom was BC positive at inclusion, 4 of whom were T2 positive, and 4 of whom were or subsequently became MAg positive).

**Kinetics of BC and Biomarker Results**

T2Candida stayed positive longer (mean [range], 3.2 [0–5] days) than BC. Eight of 9 patients with positive MAg and follow-up samples remained MAg positive during the entire observation period (up to 20 days) (Table 3).

**Clinical Classification and Performance of Diagnostic Tests**

The numbers of patients classified as proven, likely, or possible IC were 11 (8.7%), 6 (4.8%), and 11 (8.7%), respectively (Table 4; Supplementary Table 2). Abdominal IC was the most common manifestation (16/22 [72.7%]) among BC-negative patients with proven (2/5), likely (4/6), or possible IC (10/11), respectively. Significantly fewer patients with proven IC received antifungal treatment (AF) before enrollment (5/11) than among likely and unlikely cases (6/6, *P* = .004, and 82/95, *P* = .047) (Table 4).

The sensitivity was higher for T2Candida compared with BC and MAg for proven IC (55% vs 45% and 36%), for proven or likely IC (59% vs 29% and 41%), and for proven, likely, or possible IC (39% vs 8% and 32%), respectively, compared with others (Table 5); however, as the number of cases of IC was limited, these differences did not reach statistical significance. When combining the diagnostic tests, the sensitivity increased to 64%–65% for test combinations including T2Candida compared with 53%–55% for BC+MAg for proven vs others and proven/likely vs others. The specificity was high and above 90% for all tests and test combinations except T2Candida-BC-MAg triple testing for proven vs others. The PPV was higher for T2Candida than for MAg (50% vs 36% for proven and 83% vs 64% for proven/likely vs other, respectively). The negative predictive value was similar across the tests (94%–96% for proven and 90%–95% for proven/likely, respectively) but somewhat lower if including possible cases of IC (81%–88%). Overall, T2Candida combined with BC seemed to have the best diagnostic performance for proven/likely IC compared with other single tests or test combinations.

### DISCUSSION

In this study comparing the performance of diagnostic tests among high-risk ICU patients, the highest sensitivity and NPV for IC were found for T2Candida and for test combinations including T2Candida. No single test or test combination resulted in a sensitivity above 65% for IC, but the combination of T2Candida and BC seemed to have the best diagnostic performance for proven/likely IC. So far, the only other study prospectively enrolling patients before the establishment of an IC diagnosis found the T2Candida test positive in 4/6 patients with positive BCs, in line with the 4/5 found in our study [32]. In that study, a 91.1% sensitivity and 99.4% specificity for T2Candida compared with BC were estimated, enriching the sample size with 250 samples spiked with *Candida* cells at concentrations similar to what is expected during (untreated) candidemia [32]. We estimated test performance based on the clinical classification of high-risk patients, the majority of whom were suffering from deep-seated IC. We speculate that this difference in study design and the fact that many patients had received several days of antifungal therapy before enrollment may in part explain the lower performance of the T2Candida test in our setting.

The expected IC rate is around 10% among severely ill high-risk ICU patients [37]. In this study, 8.7% were classified with proven IC and additional 4.8% with likely IC. In this context, the rate of BC-proven candidiasis was notably low (4%). Most of our patients received antifungal therapy at the time of enrollment, with fluconazole being the predominating compound. Notably, none of the
Table 3. Kinetics of the Blood Culture and Biomarker Results

| Classification at Inclusion, Pt No. | Test   | Days From Study Enrollment |
|------------------------------------|--------|-----------------------------|
|                                    |        | 0  | 1–2  | 3–4  | 5–6  | 7–9  | 10–12 | 13–14 | 15–16 | 19–20 | 21  | 23  |
| Blood culture–pos. cases            |        |    |      |      |      |      |       |       |       |       |     |     |
| Proven, #63                         | BC     | T & G | Neg  |      |      |      |       |       |       |       |     |     |
|                                    | T2     | A/T  | A/T & G/K |      |      |      |       |       |       |       |     |     |
|                                    | MAg    | >500 | >500 |      |      |      |       |       |       |       |     |     |
|                                    | MAb    | Int  | Int  |      |      |      |       |       |       |       |     |     |
| Proven, #103                        | BC     | T    | T    | Neg  | T    | Neg  | Neg   | Neg   | Neg   | Neg   | Neg | Neg |
|                                    | T2     | A/T  | A/T  | Neg  | A/T  | Neg  | Neg   | Neg   | Neg   | Neg   | Neg | Neg |
|                                    | MAg    | >500 | >500 | >500 | >500 | >500 | >500  | >500  | >500  | >500  | >500 | >500 |
|                                    | MAb    | Neg  | Neg  | Int  | Int  | Int  | Int   | Int   | Int   | Int   | Int | Int |
| Proven, #4                          | BC     | G    | Neg  |      |      |      |       |       |       |       |     |     |
|                                    | T2     | G/K  | Neg  |      |      |      |       |       |       |       |     |     |
|                                    | MAg    | Neg  | Neg  |      |      |      |       |       |       |       |     |     |
|                                    | MAb    | Int  | Int  |      |      |      |       |       |       |       |     |     |
| Proven, #98                         | BC     | A    | Neg  |      |      |      |       |       |       |       |     |     |
|                                    | T2     | A/T  | A/T  |      |      |      |       |       |       |       |     |     |
|                                    | MAg    | Neg  | Neg  |      |      |      |       |       |       |       |     |     |
|                                    | MAb    | Neg  | Neg  |      |      |      |       |       |       |       |     |     |
| Proven, #33                         | BC     | C. kefyr |      |      |      |       |       |       |       |       |     |     |
|                                    | T2     | Neg  |      |      |      |       |       |       |       |       |     |     |
|                                    | MAg    | >500 |      |      |      |       |       |       |       |       |     |     |
|                                    | MAb    | Int  |      |      |      |       |       |       |       |       |     |     |
| T2Candida+, BC-neg. cases           |        |    |      |      |      |      |       |       |       |       |     |     |
| Proven (C. albicans), #89          | T2     | A/T  | A/T  |      |      |      |       |       |       |       |     |     |
|                                    | MAg    | Neg  | Neg  |      |      |      |       |       |       |       |     |     |
|                                    | MAb    | 14.2 | 11.7 |      |      |      |       |       |       |       |     |     |
| Likely (C. krusei), #60             | BC     | Neg  | Neg  | C. dubliniensis | Neg |      |       |       |       |       |     |     |
|                                    | T2     | G/K  | Neg  | P    | Neg  |      |       |       |       |       |     |     |
|                                    | MAg    | >500 | >500 | >500 | >500 | >500 | >500  | >500  | >500  | >500  | >500 | >500 |
|                                    | MAb    | 15.1 | 13.2 | 19.8 | 32.6 |      |       |       |       |       |     |     |
| Likely (C. tropicalis), #22         | T2     | A/T  | A/T  |      |      |      |       |       |       |       |     |     |
|                                    | MAg    | >500 | >500 |      |      |      |       |       |       |       |     |     |
|                                    | MAb    | Int  | 35.3 |      |      |      |       |       |       |       |     |     |
| Likely (C. albicans), #28           | T2     | A/T  | A/T  |      |      |      |       |       |       |       |     |     |
|                                    | MAg    | >500 | >500 |      |      |      |       |       |       |       |     |     |
|                                    | MAb    | Neg  | Neg  |      |      |      |       |       |       |       |     |     |
| Proven (Candida no ID), #90         | T2     | G/K  | Neg  | Neg  |      |      |       |       |       |       |     |     |
|                                    | MAg    | >500 | >500 | 250–500 |      |      |       |       |       |       |     |     |
|                                    | MAb    | Neg  | Neg  | Neg  |      |      |       |       |       |       |     |     |
| Likely (prov d-4, C. albicans), #54  | T2     | A/T  | A/T  |      |      |      |       |       |       |       |     |     |
|                                    | MAg    | Neg  |      |      |      |       |       |       |       |       |     |     |
|                                    | MAb    | Int  |      |      |      |       |       |       |       |       |     |     |
### Table 3. Continued

| Classification at Inclusion, Pt. No. | Test          | Days From Study Enrollment |
|------------------------------------|---------------|----------------------------|
|                                    | 0  | 1–2 | 3–4 | 5–6 | 7–9 | 10–12 | 13–14 | 15–16 | 19–20 | 21 | 23 |
| Possible C. albicans, #114         | T2 | A/T | Invalid | A/T | A/T | A/T | A/T | A/T | Neg |    |    |
|                                    | MAg | Neg | Neg | Neg | Neg | Neg | Neg | Neg |     |    |
|                                    | MAb | Int | Int | 37.2 | 58.6 | 58.6 | 58.6 |     |     |    |
| Possible C. albicans, #74          | T2 | Neg | Neg | G/K |     |     |     |     |     |    |    |
|                                    | MAg | Neg | Neg | 125–250 |     |     |     |     |     |    |
|                                    | MAb | Neg | Neg | 10.4 |     |     |     |     |     |    |
| Unlikely, #36                      | T2 | Neg | Neg | Neg | Neg | Neg | Neg | Neg | P | Neg |    |
|                                    | MAg | Neg | Int | 125.2 |     |     |     |     |     | Int |    |
|                                    | MAb | 20.9 | 24.7 | 45.2 | 38.9 | 37.8 | 41.1 | 39.8 | 35.2 | 40.8 |    |
| Unlikely, #83                      | T2 | Neg | P | Neg | Neg | Neg | Neg | Neg |    |    |    |
|                                    | MAg | Neg | Neg | Neg | Neg | Neg | Neg | Neg |    |    |    |
|                                    | MAb | Neg | Neg | Neg | Neg | Neg | Neg | Neg |    |    |    |
| Mannan AG–pos., T2C- and BC-neg. cases | T2 Neg |    |    |    |    |    |    |    |    |    |    |
| Unlikely, #109                     | MAg >500 |    |    |    |    |    |    |    |    |    |    |
|                                    | MAb Neg |    |    |    |    |    |    |    |    |    |    |
| Unlikely (prov d-5,-7, C. albicans), #20 | T2 Neg |    |    |    |    |    |    |    |    |    |    |
|                                    | MAg >500 |    |    |    |    |    |    |    |    |    |    |
|                                    | MAb 71.1 |    |    |    |    |    |    |    |    |    |    |
| Unlikely, #24                      | T2 Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg |    |    |    |
|                                    | MAg 125–250 | 125–250 | 125–250 | 125–250 | >250 |    |    |    |    |    |    |
|                                    | MAb 71.7 | 65.9 | 75 | 54.7 | 75.4 |    |    |    |    |    |
| Possible (Prov d+4), #121          | T2 | Neg | Neg | Neg | Neg | Neg | Neg | Neg |    |    |    |
|                                    | MAg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | 125–250 |    |    |
|                                    | MAb | Int | 11.2 | 14.6 | 19.2 | 34.7 |    |    |    |    |
| Unlikely, #70                      | T2 | Neg | Neg | Neg |    |    |    |    |    |    |    |
|                                    | MAg | 125–250 | 125–250 |    |    |    |    |    |    |    |
|                                    | MAb | Neg | Neg | Neg |    |    |    |    |    |

Empty space indicates that no samples were obtained in that time period. For patients with no BC row included, the accompanying blood cultures were negative. Patient 20 was blood culture positive with C. albicans 5 and 7 days before enrollment in the study. Mannan antigen interpretative cutoffs: Neg.: <62.5 pg/mL; Int.: ≥62.5–125 pg/mL; and Pos.: ≥125 pg/mL. Antimannan antibody interpretative cutoffs: Neg.: <5 AU/mL; Int.: 5–10 AU/mL; and Pos.: ≥10 AU/mL.

Abbreviations: BC, blood culture; Int, intermediate; MAb, mannan antibody (AU/mL); MAg, mannan antigen (pg/mL); Neg, negative; T2, T2Candida.

Fungal species abbreviations: A, Candida albicans; G, Candida glabrata; K, Candida krusei; P, Candida parapsilosis; T, Candida tropicalis.
patients with candidemia had received AF for ≥24 hours at the time of inclusion. Fluconazole (20 mg/L) reduced overall BC sensitivity by 7.5%–12.5% in a recent laboratory experiment [38]. In line with these findings, significantly fewer patients with proven infection received prior antifungal therapy in our study, a diagnosis that requires a positive culture from blood or a sterile site. In contrast, fluconazole was observed not to impact the sensitivity of the T2Candida assay in the above-mentioned laboratory study [38]. We observed a trend toward a lower T2Candida-positive rate for patients receiving antifungal therapy before sampling, suggesting that T2Candida sensitivity may also be reduced during antifungal therapy. Fluconazole therapy may lower the fungal load or clear the bloodstream despite not clearing the foci of patients with deep-seated candidiasis and hence result in a lower T2Candida sensitivity that is not observed in studies of spiked blood. It may therefore be advisable to initiate diagnostic testing before initiation of antifungals whenever feasible.

The species group provided for positive T2Candida test results was in agreement with the Candida species diagnosis established by culture from blood or other sites for patients with IC. The overall T2Candida species distribution including positives during follow-up was C. albicans/C. tropicalis 53%, C. glabrata/C. krusei 27%, and C. parapsilosis 20%. In comparison, these species accounted for 52%, 36%, and 3%, respectively, in the national surveillance program in 2012–2015 [11]. C. parapsilosis is a skin and biofilm–associated organism. None of the 3 patients with a positive C. parapsilosis T2Candida result were diagnosed as IC or colonized with C. parapsilosis by culture. We therefore regard these findings as contaminations, illustrating the importance of thoroughly decontaminating the skin or catheter before blood draws for T2Candida. In settings with a higher true prevalence of C. parapsilosis infections like in neonates and in endemic areas such as Latin America, Southern Europe, and Asia, it may be difficult to differentiate clinically relevant C. parapsilosis findings from contaminations, potentially leading to unnecessary use of antifungal therapy [39].

T2Candida is an expensive diagnostic tool. At the time of writing, the price in our country for a test kit is US$300 per sample, and an annual fee for a service contract of US$15 500. Although cost analyses have suggested lower candidemia-related inpatient costs and mortality with implementation of the T2Candida test [40], cost may be prohibitive in some settings, particularly at a time of declining cost for the echinocandins. The combination of MAg with BC was superior to BC alone. However, in addition to being less sensitive compared with T2Candida alone and when combined with BC, a drawback is that species identification is not provided for MAg-positive samples to inform whether the species is a likely target for de-escalation to fluconazole once the patient is stable.

Table 4. Performance of Blood Culture, T2Candida, and Mannan Antigen Based Upon the 2 Initial Blood Sample Sets for Patients Classified With Proven (11), Likely (6), Possible (11), or Unlikely (98) Invasive Candidiasis

| Final Classification | No. of Patients | No. w/ Prior AF | BC Pos | T2 Pos | MAg Pos |
|----------------------|----------------|----------------|--------|--------|---------|
| Proven               | 11             | 5/11           | 5/11   | 6/11   | 4/11    |
| Candidemia within ±3 d of inclusion | 6               | 2**           | 5/6   | 5/6   | 3/6   |
| Abdominal candidiasis incl. aortoprosthesis | 1             | 0            | 0      | 0      | 0      |
| Abdominal candidiasis | 1            | 1*            | 0      | 1/1   | 1/1    |
| Mediastinal or pleural candidiasis | 2            | 2H*           | 0      | 0      | 0      |
| Polymicrobial necrotizing fasciitis | 1            | 0            | 0      | 0      | 0      |
| Likely               | 6              | 6/6           | 0/6    | 4/6    | 3/6    |
| Abdominal candidiasis & prior proven abdominal candidiasis | 3            | 3**B,*.     | 0     | 1/3   | 0      |
| Abdominal candidiasis | 1            | 1*            | 0      | 1/1   | 1/1    |
| Pulmonary candidiasis in hematological Pt | 1             | 1*            | 0      | 1/1   | 1/1    |
| Tissue candidiasis   | 1              | 1*            | 0      | 1/1   | 1/1    |
| Possible             | 11             | 10/11         | 0/11   | 1 &1 d4/11 | 2/11 |
| Abdominal candidiasis & prior proven candidemia, d –5 & –7 | 8          | 7**B,*.        | 0     | 1 &1 d4/8 | 1/8 |
| Abdominal candidiasis & proven, d +4 | 1             | 1*            | 0      | 0      | 1/8    |
| Renal candidiasis & prior proven | 1             | 1*            | 0      | 0      | 0      |
| Unlikely             | 98             | 82/95f        | 0/98   | 17/98  | 2/98   |

Information on prior systemic antifungal therapy at inclusion is indicated (No. w/ Prior AF).
Abbreviations: AF, antifungal treatment; BC, blood culture; MAg, mannan antigen (pg/mL); T2, T2Candida.
*Duration of AF before inclusion: <1 day.
BDuration of AF before inclusion: 1–3 days.
BDuration of AF before inclusion: 4–7 days.
BDuration of AF before inclusion: >7 days.
BNo information on duration of AF before inclusion.
*Information on prior antifungal therapy was missing for 3/98 patients.
B*Candida parapsilosis.
Table 5. Performance Characteristics for the Diagnostic Tests Using the Clinical Classification of Proven (11), Likely (6), Possible (11), or Unlikely Invasive Candidiasis (98) as the Gold Standard

| Candidiasis Classification and Diagnostic Test | Sensitivity, % | Specificity, % | PPV, % | NPV, % |
|-----------------------------------------------|---------------|---------------|-------|-------|
| Proven vs others                              |               |               |       |       |
| BC                                            | 45            | 100           | 100   | 95    |
| T2                                            | 55            | 93            | 50    | 96    |
| Mag                                          | 36            | 94            | 36    | 94    |
| T2+BC                                         | 64            | 93            | 54    | 96    |
| T2+Mag                                        | 64            | 89            | 41    | 96    |
| BC+Mag                                       | 55            | 94            | 38    | 96    |
| T2+BC+Mag                                    | 64            | 89            | 41    | 96    |
| Proven or likely vs others                    |               |               |       |       |
| BC                                            | 29            | 100           | 100   | 90    |
| T2                                            | 59            | 96            | 83    | 94    |
| Mag                                          | 41            | 96            | 64    | 91    |
| T2+BC                                         | 65            | 96            | 85    | 95    |
| T2+Mag                                        | 65            | 92            | 65    | 94    |
| BC+Mag                                       | 53            | 96            | 54    | 93    |
| T2+BC+Mag                                    | 65            | 92            | 65    | 94    |
| Proven, likely, or possible vs unlikely       |               |               |       |       |
| BC                                            | 18            | 100           | 100   | 81    |
| T2                                            | 39            | 97            | 92    | 85    |
| Mag                                          | 32            | 98            | 82    | 83    |
| T2+BC                                         | 43            | 97            | 92    | 86    |
| T2+Mag                                        | 50            | 95            | 82    | 88    |
| BC+Mag                                       | 39            | 98            | 85    | 85    |
| T2+BC+Mag                                    | 50            | 98            | 82    | 88    |

Abbreviations: BC, blood culture; Mag, mannan antigen; NPV, negative predictive value; PPV, positive predictive value; T2, T2Candida.

The time to negativity was longer for the T2Candida test than for BC, supporting recent findings [41]. This may suggest that whereas the appropriate duration of therapy after resolution of symptoms and BC negativity is 14 days, this may be shorter after resolution of symptoms and T2Candida negativity [42]. In contrast, the mannan antigen remained positive throughout the observation period and up to 14 days after BC documented clearance of the bloodstream and thus should not alone prompt continued antifungal therapy.

This study has limitations. First and foremost, the number of proven and likely cases was limited, and more than half of the proven IC cases were BC negative at the time of inclusion, suggesting a low amount of circulating Candida cells. Therefore, numbers were insufficient for statistical comparative analysis of the diagnostic tests. In the absence of a reliable gold standard for the diagnosis of IC, classification of patients was done adopting the EORTC/MSG definitions for proven infection and criteria adopted from 2 recent studies for likely and possible IC [9, 25, 36]. A positive blood culture defined proven infection, and a highly positive Mag in a colonized patient with clinical signs and symptoms defined likely IC, whereas a positive T2Candida did not. Consequently, the relative diagnostic performance of T2Candida compared with BC and Mag may have been underestimated. Most of the patients with deep-seated IC were patients with complicated infections receiving broad-spectrum antibiotics in whom it is difficult to dissect the clinical significance of the findings of Candida in microbiological samples. Finally, colonization was difficult to compare, as neither sampling nor mycologic examination was standardized.

In conclusion, our study underscores the complexity associated with diagnosing IC. Most patients were BC negative, probably in part because the majority were already on fluconazole prophylaxis, as recommended in a multimorbod high-risk population. T2Candida was the biomarker that contributed the most to improving the diagnostic sensitivity while retaining a good specificity and NPV. This makes it a promising addition to the diagnostic armamentarium. However, our study also suggests that maximal benefit of diagnostic efforts may require that sampling is initiated as early as possible, preferably before initiation of antifungal therapy, when the sensitivity and NPV of T2Candida and BC testing are maximal and probably sufficient for excluding IC.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

Author contributions. The study was designed by M.C.A., J.S., and J.S.A. N.R., J.S.A., K.K., and M.K.H. were responsible for enrollment and data collection. M.C.A. was responsible for laboratory tests. M.H. reviewed patient records and analyzed the data. The clinical classification was done by M.H. and M.C.A. The manuscript was drafted by M.C.A. and M.H. and reviewed and approved by all authors.

Financial support. This work was supported in part (test kits provided, and part of the hourly fee for the ICU doctors spent on patient record review was reimbursed to the ICU departments) by T2Biosystems. MCA has received research grants from Savværkskejer Jeppe Juhs og hustru Ovita Juhs Mindelegat. 295 MH received support from the Danish National Research Foundation, grant #126.

Availability of data. Data are not publicly available.

Potential conflicts of interest. M.C.A. has received personal speaker honoraria in the past 5 years from Astellas, Basilea, Gilead, MSD, Pfizer, T2Biosystems, and Novartis. She has received research grants and contract work payment, paid to the Statens Serum Institute, from Astellas, Basilea, Gilead, T2Biosystems, F2G, Cidara, and Amplyx. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med 2015; 373:1445–56.
2. Arendrup MC, Sulim S, Holm A, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 2011; 49:3300–8.
3. Bassetti M, Righi E, Ansaldi F, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med 2015; 41:1601–10.
4. Cleveland AA, Harrison LH, Fuerly MM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance. PLoS One 2015; 10:e0120452.
5. Doi AM, Pignatari AC, Edmond MB, et al. Epidemiology and microbiologic characterization of nosocomial candidemia from a Brazilian National Surveillance Program. PLoS One 2016; 11:e0146909.
6. Rajendran R, Sherry L, Deshpande A, et al. A prospective surveillance study of candidaemia: epidemiology, risk factors, antifungal treatment and outcome in hospitalized patients. Front Microbiol 2016; 7:915.

7. Andes DR, Safdar N, Baddley JW, et al; Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1180–22.

8. Lortholary O, Renaudat C, Sitbon K, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med 2014; 40:1303–12.

9. De Paauw B, Walsh TJ, Donnelly JP, et al; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813–21.

10. Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013; 56:1284–92.

11. Astwood EMT, Johansen HK, Rader BL, et al. Update from a 12-year nationwide fungemia surveillance: increasing intrinsic and acquired resistance concerns. J Clin Microbiol 2018; 56:e01564–17.

12. Ericson EL, Klingspor L, Ullberg M, Ozenci V. Clinical comparison of the Bactec 9240 and BacT/ALERT 3D automated blood culture systems for Candida; 73:153–6.

13. Horvath LL, George BJ, Murray CK, et al. Direct comparison of the BACTEC 1240 and BacT/ALERT 3D automated blood culture systems for Candida growth detection. J Clin Microbiol 2004; 42:115–8.

14. Clancy CJ, Pappas PG, Vazquez J, et al. Detecting Infections Rapidly and Easily (FUNGINOS). β-glucan antigenemia anticipates diagnosis of blood culture-negative candidemia: epidemiology, risk factors, antifungal treatment and outcome in intensive care unit patients: a randomized pilot study. PLoS One 2012; 7:e42282.

15. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. Time to initiation of fluconazole therapy for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60:892–9.

16. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of invasive candidiasis. J Clin Microbiol 2004; 42:1813–21.

17. Parkins MD, Sabuda DM, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2005; 49:3640–5.

18. Klevay MJ, Ernst EJ, Hollanbaugh IL, et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2008; 60:273–7.

19. Cuenca-Estrella M, Verweij FE, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida species 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18(Suppl 7):9–18.

20. León C, Ruiz-Santana S, Saavedra P, et al; Cava Trem Study Group. Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care 2016; 20:149.

21. Hansen KE, Pfeiffer CD, Lease ED, et al. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 2012; 7:e42282.

22. Tilson E, Lantho E, Hauser PM, et al; Fungal Infection Network of Switzerland (FUNGINOS). β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 2013; 188:1100–9.

23. Harli B, Zeller I, Manhart A, et al. A retrospective assessment of four antigen assays for the detection of invasive candidiasis among high-risk hospitalized patients. Mycopathologia 2018; 183:513–9.

24. Mohr JE, Sims C, Paetznick V, et al. Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011; 49:58–61.

25. Martinez-Jimenez MC, Muñoz P, Valerio M, et al. Combination of Candida bio-markers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment. J Antimicrob Chemother 2017; 72:107–15.

26. Racil Z, Kocmanova I, Lengova M, et al. Difficulties in using L-3-(beta)-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies—high frequency of false-positive results and their analysis. J Med Microbiol 2010; 59:1016–22.

27. Verduny Lunel FM, Donnelly JP, van der Lee HA, et al; Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin Microbiol Infect 2009; 15:380–6.

28. Mikulasí M, Calandra T, Sanguinetti M, et al. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010; 14:R222.

29. Arendrup MC, Bergmann OJ, Larsson L, et al. Detection of candidaemia in patients with and without underlying haematological disease. Clin Microbiol Infect 2010; 16:855–62.

30. Duerrmann W, Koidl C, Krause R, et al. Specificity of mannan antigen and anti-mannan antibody screening in patients with haematological malignancies at risk for fungal infection. Mycoses 2016; 59:374–8.

31. Sendid B, Poulet JL, Tabouret M, et al. Combined detection of mannanemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002; 51:433–42.

32. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60:892–9.

33. Beyda ND, Alam MJ, Garey KW. Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagn Microbiol Infect Dis 2013; 77:324–6.

34. Hamula CL, Hughes K, Fisher BT, et al. T2Candida provides rapid and accurate species identification in pediatric cases of candidemia. Am J Clin Pathol 2016; 145:858–61.

35. Lausch KR, Seggaard M, Rensingve F, et al. High incidence of candidaemia in a nationwide cohort: underlying diseases, risk factors and mortality. Int J Infect Dis 2018; 76:58–63.

36. Ostrosky-Zeichner L, Shoahm S, Vazquez J, et al. MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 2014; 58:2129–26.

37. Ostrosky-Zeichner L, Pappas PG, Shoahm S, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2011; 54:46–51.

38. Beyda ND, Amadio J, Rodriguez JR, et al. In vitro evaluation of BacT/Alert FA blood culture bottles and T2Candida assay for detection of Candida in the presence of antifungals. J Clin Microbiol 2018; 56:e00471–18.

39. Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers 2018; 4:18026.

40. Bilir SP, Ferrufino CP, Pfaffer MA, Munakata J. The economic impact of rapid Candida species identification by T2Candida among high-risk patients. Future Microbiol 2015; 10:1133–44.

41. Mylonakis E, Zacharioudakis IM, Clancy CJ, et al. The efficacy of T2 magnetic resonance assay in monitoring candidemia after the initiation of antifungal therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) trial. J Clin Microbiol 2018; 56:e01756–17.

42. Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18(Suppl 7):19–37.